Current and Future Use of MET Inhibitors in NSCLC
April 26th 2021Healthcare professionals who manage patients with non–small cell lung cancer comment on their current experience using MET inhibitors as treatment for patients who harbor MET exon 14 skipping mutations and highlight strategies under investigation that will hopefully address current gaps in therapy.
Read More
MET Inhibitors in NSCLC: Mechanisms of Resistance
April 26th 2021The rationale for using MET inhibitors as first-line therapy for patients with non–small cell lung cancer who harbor MET exon 14 skipping mutations and considerations for sequencing later lines of therapy based on what is known to date about mechanisms of resistance to MET inhibitors.
Read More
Dr. Joshua M. Bauml on Pembrolizumab Versus Chemo in Head and Neck Cancers
August 16th 2016Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the differences between pembrolizumab (Keytruda) and cytotoxic chemotherapies.
Read More
Dr. Bauml on KEYNOTE-055 Study for Patients With HNSCC
June 30th 2016Joshua M. Bauml, MD, assistant professor of Medicine, Hospital of the University of Pennsylvania and the Veteran's Administration Medical Center, discusses the preliminary results of the KEYNOTE-055 study, which investigated pembrolizumab (Keytruda) after failure on platinum-based therapy and cetuximab in patients with head and neck squamous cell carcinoma.
Read More